Predictors and Impact of Total Occlusion of the Infarct-Related Coronary Artery on Short-Term Outcomes
NCT ID: NCT07086807
Last Updated: 2025-07-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2000 participants
OBSERVATIONAL
2011-01-01
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Acute and Long-term Outcomes of Patients With Acute Myocardial Infarction Treated With PCI
NCT04506047
Coronary Angiography in Critically Ill Patients With Type II Myocardial Infarction
NCT04043091
Cardiovascular Magnetic Resonance for the Occluded Infarct-Related Artery Treatment
NCT00968383
Intramyocardial Haemorrhage in Patients With Primary STEMI
NCT03677466
CardiOvascular Risk and idEntificAtion of Potential High-risk Population in Acute Myocardial Infarction II (COREA-AMI II)
NCT02806102
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients will be excluded if they are treated without PCI, are diagnosed with myocardial infarction with non-obstructive coronary arteries (MINOCA), or undergo surgical revascularization (coronary artery bypass grafting).
Data will be collected from the hospital electronic medical records and patient charts. Mortality data will be obtained from the Croatian National Institute of Public Health cause-of-death registry. Collected variables will include baseline demographic data, medical history, chronic pre-admission pharmacotherapy, in-hospital course, complications, and procedural characteristics. All angiograms will be re-evaluated independently by two experienced interventional cardiologists. Chronic pharmacotherapy will be considered relevant if the patient has been taking the medication for at least four weeks prior to the index event. Significant carotid artery stenosis will be defined as a luminal narrowing of more than 50%.
Patients will be divided into two groups based on the patency of the infarct-related artery (IRA): those with an occluded coronary artery (OCA group) and those with a patent coronary artery (PCA group). A patent artery will be defined as having visible antegrade flow of at least TIMI grade I distal to the culprit lesion. Occlusion will be defined as complete absence of antegrade flow beyond the site of the lesion (TIMI 0), with no visible antegrade or retrograde collateral circulation. All the patients will be pretreated with 300 mg of acetylsalicylic acid and 600 mg of clopidogrel or 180 mg of ticagrelor, depending on current guidelines.
All patients will be followed until the primary endpoint is reached or for 30 days from the index hospitalization. The primary clinical endpoint will be all-cause mortality during the follow-up period.
Statistical analysis will be performed using appropriate methods depending on data distribution. Continuous variables will be expressed as medians with interquartile ranges or as means with standard deviations, as appropriate. Normality of distribution will be assessed using the Shapiro-Wilk test. To assess statistical significance between groups, the Mann-Whitney test will be used for continuous variables, and the χ² test for discrete variables. A two-sided p-value of \<0.05 will be considered statistically significant. Due to multiple comparisons, adjustment by the Benjamini-Hochberg method will be applied.
Evaluation of survival over the 30-day follow-up period will be performed using Kaplan-Meier survival curves, and the log-rank test will be used to compare survival rates between groups. Cox proportional hazards regression analysis will be used to identify independent predictors of 30-day mortality. To assess independent predictors of an occlusive type of myocardial infarction, logistic regression analysis will be employed. The statistical analysis will be performed using SPSS Version 20 (IBM SPSS Statistics, New York, USA).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with occluded IRA
Patients with acute occlusion (TIMI 0) of the infarct-related artery (IRA) at the time of the coronary intervention due to acute myocardial infartion
No interventions assigned to this group
Patients with patent IRA
Patients with acute non-occlusion (TIMI 1-3) of the infarct-related artery (IRA) at the time of the coronary intervention due to acute myocardial infartion
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* diagnosed with myocardial infarction with non-obstructive coronary arteries (MINOCA),
* underwent surgical revascularization (coronary artery bypass grafting).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital Sestre Milosrdnice
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nikola Kos
MD, PhD, cardiologist
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KBSestreMil
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.